Background: Treatment adherence (TA) is a prerequisite to achieve the goals of asthma therapy. Clinical trials have shown significant therapeutic benefits of extrafine formulation single-inhaler triple therapy (efSITT) consisting of beclometasone dipropionate/formoterol fumarate/glycopyrronium in the treatment of patients with asthma. TA under real-life conditions often differs significantly from that in clinical trials. The impact of efSITT on TA in patients with asthma in real-world practice is yet to be evaluated.
Aims and objectives: The TriMaximize study aims to provide the characteristics, therapy pathways and health-related outcomes of patients with moderate-to-severe asthma prescribed efSITT in real-world practice. We present an interim analysis of the changes in TA in the first 292 patients from Germany, United Kingdom, Austria and Denmark after three months of treatment with efSITT.
Methods: This is a multicenter, multinational, prospective, observational study following patients with asthma for 1?3 years. TA is assessed using the Test of Adherence to Inhalers.
Results:
| TA score | Proportion of patients at baseline (V1) | Proportion of patients at 3 months (V2) | Change V2-V1 (p<0.0001, Chi-squared test) |
| Poor | 26% | 19.2% | -6.8% |
| Medium | 28.1% | 27.4% | -0.7% |
| Good | 45.9% | 53.4% | 7.5% |
49% of patients with a poor or medium TA score at baseline improved to a higher TA category (p<0.0001, Chi-squared test).
Conclusions: Our data show a significant improvement in TA in patients with moderate-to-severe asthma after three months of treatment with efSITT following a switch from ICS/LABA or ICS/LABA/LAMA.